Addressing Unmet Need

Today, over 32 million cancer survivors worldwide face the risk of recurrent cancer. Patients are told they are “cancer-free” only to discover that a few undetectable cancer cells survived initial treatment and they have to face another battle with cancer. It is the reality that chemotherapy, radiation therapy and even multimodal therapies, often result in only partial and temporary disease control. Frezent was established with a mission to bring a game-changing approach into treating cancer and to develop a new therapeutic modality that will significantly decrease the risk of cancer recurrence.

Our Approach

Most therapies are designed to prevent tumor growth by attacking rapidly dividing cancer cells. Frezent is developing a novel class of bifunctional therapeutic modalities, bispecific antibodies and antibody-drug conjugates, to target non-dividing, dormant cancer cells. Frezent’s bifunctional antibodies block essential metabolic programs in dormant cancer cells and as a result, they prevent dormant cancer cell transformation into recurrent cancer.